Company intelligence / Profile preview

Exothera

Jumet, Wallonia, Belgiumexothera.world ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Exothera provides end-to-end process development, optimization, analytical testing, regulatory consultation, and GMP/commercial manufacturing services for viral vectors and nucleic acids. They are recognized for rapid project delivery using advanced technologies such as Scale-X™, iCellis™, and the Quantoom Ntensify® platform. The company has supported over 58 projects since its founding in 2020 with high customer satisfaction (>95%).

Modalities: Viral vector-based therapyRNA therapy (including mRNA-based drugs)Vaccine (viral vector and RNA-based)Oncolytic virus therapy
Industry: Contract Manufacturing Organization

Partnerships

Collaborates with multiple biotech/pharma companies via service agreements.

Beyond the preview

Go deeper on Exothera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exothera.

Explore the full profile